Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Declines By 19.0%

iTeos Therapeutics, Inc. (NASDAQ:ITOS) was the recipient of a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 1,280,000 shares, a decline of 19.0% from the February 13th total of 1,580,000 shares. Based on an average daily trading volume, of 362,400 shares, the days-to-cover ratio is presently 3.5 days. Approximately 3.9% of the company’s shares are sold short.

iTeos Therapeutics Trading Down 3.7 %

Shares of ITOS stock traded down $0.27 on Tuesday, reaching $7.09. 401,566 shares of the stock were exchanged, compared to its average volume of 457,405. The company has a market capitalization of $270.80 million, a price-to-earnings ratio of -2.25 and a beta of 1.38. The business’s 50 day moving average price is $7.46 and its 200 day moving average price is $8.93. iTeos Therapeutics has a twelve month low of $6.67 and a twelve month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.13. Equities research analysts forecast that iTeos Therapeutics will post -3.49 earnings per share for the current year.

Analysts Set New Price Targets

ITOS has been the subject of a number of research analyst reports. Wedbush restated an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a report on Wednesday, March 5th. JPMorgan Chase & Co. lowered their price objective on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday, March 6th. Wells Fargo & Company lowered their target price on iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, March 6th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price target on shares of iTeos Therapeutics in a research report on Thursday, March 6th.

Hedge Funds Weigh In On iTeos Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Point72 DIFC Ltd purchased a new stake in shares of iTeos Therapeutics during the 3rd quarter worth approximately $31,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in iTeos Therapeutics in the fourth quarter valued at $42,000. Virtus ETF Advisers LLC lifted its position in iTeos Therapeutics by 58.2% in the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock valued at $69,000 after acquiring an additional 3,293 shares during the last quarter. Forefront Analytics LLC acquired a new position in iTeos Therapeutics in the fourth quarter valued at $85,000. Finally, Graham Capital Management L.P. purchased a new position in shares of iTeos Therapeutics during the fourth quarter worth about $85,000. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.